An Efficacy of Continuing Tenofovir Versus Switching Entecavir to Tenofovir in Treatment of Chronic Hepatitis B Patients : A Comparative Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160125002

Enrollment

300

Registered

2016-01-25

Start date

2016-01-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B Chronic hepatitis B Tenofovir Entecavir Switching

Interventions

Received Tenofovir 300 mg od for 5 years then continue Tenofovir 300 mg od for 5 year,Received Entecavir 0.5 mg od for 5 years then switching to Tenofovir 300 mg od for 5 year

Active Comparator Drug,Experimental Drug

Continuing Tenofovir,Switching Entecavir to Tenofovir

Eligibility

Sex/Gender

All

Age

20 Years to 0 Years

Inclusion criteria

Inclusion criteria: 1. Chronic hepatitis B patient 2. serum HBsAg positive after received Entecavir or Tenofovir for more than 5 year

Exclusion criteria

Exclusion criteria: 1. History of malignancy, except early stage skin cancer 2. Decompensated cirrhosis 3. Creatinine clearance < 50 ml/min 4. Kanofsky performance status < 60 5. Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Efficacy year 1, 2, 3, 4, 5 HBsAg loss, HBeAg loss, HBeAg seroconversion, HBV DNA suppression,HCC during study period Ultrasound	—

Secondary

Measure	Time frame
Safety every 6 month Creatinine, Phosphate	—

Countries

Thailand

Contacts

Public ContactTeerapat Ungtrakul

Chulabhorn Hospital

ungteerapat@yahoo.com025766791

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026